NARA Discovery
Article Details
← Back to Search Results
Journal Article

Mo-CBP3-PepIII Changes the Proteomic Profile of Gastric Cancer Cells, Induces Membrane Pore Formation, and ROS Overaccumulation

Talia Rabelo Oliveira; Felipe Pantoja Mesquita; Daiane Maria Silva Brito; Antonia Catarine Gomes Vieira; Emerson Lucena da Silva; Laís Lacerda Brasil-Oliveira; Maria Elisabete Amaral de Moraes; Pedro Victor da Rocha Lima; Raquel de Carvalho Montenegro; Pedro Filho Noronha de Souza
International Journal of Peptide Research and Therapeutics · Vol. 32, Issue 3 · 2026

Abstract

Background Synthetic peptides have gained prominence due to their potential structural alterations and selective toxicity. In this context, Mo -CBP 3 -PepIII, derived from Moringa oleifera , was developed to increase selectivity against tumor cells. This study evaluated its activity in AGS cells and demonstrated low toxicity in non-tumor cells, MNP-01. Its mechanism of action was investigated using membrane integrity analyses, reactive oxygen species accumulation, morphological alterations assessed by scanning electron microscopy, and proteomics. Findings The results indicate increases of 2.5-, 2.8-, and 1.5-fold, respectively, in membrane permeability, pore formation, and ROS accumulation in peptide-treated cells compared to controls. Scanning electron microscopy revealed that Mo-CBP3-PepIII-treated cells were severely damaged compared with control cells. Additionally, proteomic analysis identified 3052 proteins in control cells (1970) and treated cells (1532). A deeper look into differentially accumulated proteins revealed that Mo-CBP3-PepII interfere in the accumulation of proteins required for cancer cell growth, development and maintenance, drug resistance. Conclusion Therefore, future studies should delve deeper into its effects on apoptosis, migration, and tumor invasion, examine the cell signaling pathways involved, and explore the proteins identified in this study to understand their functions in tumor biology and the possible interactions of Mo-CBP3-PepIII with conventional drugs.

Bibliographic Information

JournalInternational Journal of Peptide Research and Therapeutics
PublisherSpringer
Publication Date2026-04-18
Publication Year2026
Volume32
Issue3
Document TypeJournal Article
eISSN1573-3904
DOI10.1007/s10989-026-10826-2

Access Information

NARA Access Coverage1994-01-01~Current
Journal Homepagehttps://www.springer.com/journal/10989
Publisher PageOpen Publisher Page
Full-text access depends on NARA's subscribed coverage and institutional access.